Table 1. Studies of chemotherapy-induced thrombotic microangiopathy treated with eculizumab.
| Patients (n) |
Drug | Previous therapy | Doses of eculizumab (range) / duration of treatment | Median follow-up (range) | Improved renal outcome | Genetic analysis | Reference |
|---|---|---|---|---|---|---|---|
| 1 | Gemcitabine | DW + TPE + Steroids + RTX | 4 / 3 weeks | 17.5 weeks | Yes | NT | Starck [34] 2014 |
| 1 | Mitomycin C | DW + TPE | 8 / 3 months | 18 months | Yes | NT | Faguer [35] 2013 |
| 1 | Cisplatin | DW | Not reported / 4 months | Not reported | Yes, relapse 2 months after stop of eculizumab | CD46 mutation | Gilbert [36] 2013 |
| 4 | Gemcitabine | DW + TPE in 1 patient DW + steroids in 1 patient DW in 2 patients |
6.25 (5 – 8) / not reported | Not reported | Yes | NT | Al-Ustwani [37] 2014 |
| 1 | Gemcitabine | DW + TPE | 4 / not reported | 11 weeks | No | ND | Tsai [38] 2014 |
| 1 | Gemcitabine | DW + Steroids | 6 / 7 weeks | 3 months | No | NT | Karkowsky [39] 2015 |
| 1 | Gemcitabine | DW + TPE | 7 / 10 weeks | Not reported | Yes | NT | Rogier [16] 2016 |
| 1 | Gemcitabine | DW + TPE | 7 / 8 weeks | 3 months | Yes | NT | Lopez [40] 2017 |
| 8 | Gemcitabine | DW | 4.5 (3 – 22) / not reported | Not reported | Yes | NT | Grall [41] 2016 |
| 7 | Gemcitabine Dasatinib Bevacizumab Bleomycin |
DW DW + TPE (2 patients) |
Not reported / 14 weeks (2 – 24 weeks), 1 ongoing |
Not reported | Yes | NT | Weitz/Deloughery [42] 2018 |
| 2 | Gemcitabine Carfilzomib |
DW + TPE | Not reported | 42.5 weeks (33-52) | Yes | NT | Gosain [43] 2017 |
| 1 | Gemcitabine | DW + TPE | 20 / 9 months | 17 months | Yes | NT | Krishnappa [44] 2018 |
DW = offending drug withdrawn; TPE = therapeutic plasma exchange; RTX = rituximab; NT = not tested; ND = not detected.